leisure time -WSS

leisure time

author：entertainment 2025-09-28 23:30:46 - browse：9778

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： David Liu startup to focus on CRISPR delivery

focus

WSS

Covid’s new normal has set in amid another rise in cases

Eli Lilly CEO gives to Mike Pence presidential super PAC

The White House hikes tariffs on plastic syringes made in China

Midwives could help bridge maternal health disparities in the U.S.

WuXi Biologics beefs up its lobbying operation

Information blocking fines are now fair game in health care

hotspot

leisure time

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Obesity drug from Roche shows promise in early study

Peter Hotez and the public health issue of online harassment

HHS suspends federal funding for EcoHealth Alliance

Supreme Court strikes down use of affirmative action

Oak Street deal isn't the answer to health care's woes

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Activists slam private health insurers over coverage restrictions

CVS is willing to dump 10% of its Medicare Advantage members

entertainment

STAT series 'Denied by AI' wins major journalism prizes

Grad students accuse University of California of wage theft

WuXi Biologics execs register to lobby as Congress comes for the company

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Galapagos to make CAR

WuXi Biologics beefs up its lobbying operation

entertainment

focus

hotspot

focus